Global Information
회사소개 | 문의 | 비교리스트

Plasmid DNA 제조 시장 : 규모, 점유율, 전망, 기회 분석(2018-2026년)

Plasmid DNA Manufacturing Market - Size, Share, Outlook, and Opportunity Analysis, 2018- 2026

리서치사 Coherent Market Insights
발행일 2019년 04월 상품 코드 833140
페이지 정보 영문
가격
US $ 4,500 ₩ 5,431,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 8,449,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 12,070,000 PPT Turned PDF (Enterprise User License)


Plasmid DNA 제조 시장 : 규모, 점유율, 전망, 기회 분석(2018-2026년) Plasmid DNA Manufacturing Market - Size, Share, Outlook, and Opportunity Analysis, 2018- 2026
발행일 : 2019년 04월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

Plasmid DNA(pDNA)는 유전자 치료 또는 백신 항원 생성 치료제로서 직접적으로, 그리고 다양한 연구 분야에서 간접적으로 사용할 수 있습니다. 이러한 용도에는 렌티바이러스 또는 아데노 수반 바이러스(AAV) 등의 바이러스 벡터 구축과 단클론항체 등의 개발중인 일시성 단백질 양쪽 모두를 생산하기 위한 일시적 주입법(transient transfection)의 중요 출발 재료로서의 사용이 포함됩니다. pDNA는 새로운 바이오 의약품 생산이나 RNA, 생체외 단백질 생산, 세포치료 등의 프로세스를 지원하기 위한 마스터 템플릿 제품으로서 사용되고 있습니다.

세계의 Plasmid DNA 제조 시장을 조사했으며, 시장 개요, 종류, 지역별 시장 동향, 시장 규모 추이와 예측, 시장 성장 촉진요인 및 저해요인, 시장 기회 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 조사 목적과 전제조건

  • 조사 목적
  • 전제조건
  • 약어

제2장 시장 범위

  • 보고서에 대해
    • 시장 정의와 범위
  • 주요 요약
    • 제품 종류별 시장
    • 용도별 시장
    • 지역별 시장
  • Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
  • 시장 동향
  • 영향 해석
  • 주요 하이라이트
  • PEST 분석
  • Porter의 분석
  • 인수합병(M&A)
  • 역학

제4장 제품 종류별 시장, 2018-2026년(백만 달러)

  • 서론
  • High Quality (HQ) Plasmid DNA
  • GMP Grade Plasmid DNA
  • Non-GMP Grade Plasmid DNA

제5장 용도별 시장, 2018-2026년(백만 달러)

  • 서론
  • DNA 백신
  • 유전자 치료
  • 면역치료
  • 기타

제6장 지역별 시장, 2018-2026년(백만 달러)

  • 서론
  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양
  • 중동
  • 아프리카

제7장 경쟁 구도

  • 히트 맵 분석
  • 시장 점유율 분석
  • 기업 개요
    • Cobra Biologics and Pharmaceutical Services
      • 제품 종류 포트폴리오
    • VGXI, Inc.
    • Aldevron
    • 가네카
    • Nature Application Corporation
    • PlasmidFactory GmbH & Co. KG
    • Cell and Gene Therapy Catapult
    • Waisman Biomanufacturing
  • 애널리스트의 견해

제8장 섹션

  • 참고 문헌
  • 조사 방법
  • Coherent Market Insights에 대해
LSH 19.05.20

Plasmid DNA (pDNA) can be used directly as a therapeutic agent in gene therapy or generation of vaccine antigens, and indirectly in a range of research applications. These applications include its use as a critical starting material for transient transfection to produce both viral-vector constructs such as lentivirus or Adeno-associated virus (AAV) and transient proteins in development such as monoclonal antibody. pDNA is used as a master-template product to support production of new and emerging biopharmaceutical products and processes including RNA, in-vitro protein production, and cell therapies.

Plasmids used as therapeutic agents tend to be relatively small in size (4.5- 6.0 kb and even down to 2.5 kb), requiring relatively low quantities to support early phase clinical trials (1-5 g of purified pDNA). These advantages make plasmid DNA more suitable to carry out late phase clinical trials.

Increasing demand for plasmid DNA (pDNA) and increasing research and development activities are major factors driving the plasmid DNA manufacturing market growth. For instance, in April 2018, PlasmidFactory GmbH & Co. KG acquired new laboratory space to expand research and development activities and production of plasmid DNA.

Cobra Biologics, a U.K.-based contract development and manufacturing organization (CDMO) has been producing plasmid DNA for a number of clinical applications for over 15 years at an approved site in the U.K. under the European Union (EU) clinical trials directive.

The company developed its own manufacturing process for production and purification of pDNA with related proprietary technologies, which include an antibiotic-free plasmid maintenance system, operator repressor titration (ORT), and cell-lysis technologies (2-4). Moreover, company successfully executed over 240 DNA programs with process development, manufacturing, and stability studies for over 35 different customers, globally. Generated plasmids have been used in clinical trials for gene therapy and vaccines as well as in viral vector production.

Moreover, large scale companies are actively focusing on strategic partnerships for drug development activity, which is expected to drive the market growth over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the plasmid DNA manufacturing market and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global plasmid DNA manufacturing market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Cobra Biologics and Pharmaceutical Services, VGXI, Inc., Aldevron, Kaneka Corporation, Nature Application Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, and Waisman Biomanufacturing
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, market expansion, and marketing tactics
  • The global plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the plasmid DNA manufacturing market

Detailed Segmentation:

  • Global Plasmid DNA Manufacturing Market, By Product Type:
    • High Quality (HQ) Plasmid DNA
    • GMP Grade Plasmid DNA
    • Non-GMP Grade Plasmid DNA
  • Global Plasmid DNA Manufacturing Market, By Application:
    • DNA Vaccines
    • Gene Therapy
    • Immunotherapy
    • Others
  • Global Plasmid DNA Manufacturing Market, By Region:
    • North America
      • By Product Type:
      • High Quality (HQ) Plasmid DNA
      • GMP Grade Plasmid DNA
      • Non-GMP Grade Plasmid DNA
      • By Application:
      • DNA Vaccines
      • Gene Therapy
      • Immunotherapy
      • Others
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Product Type:
      • High Quality (HQ) Plasmid DNA
      • GMP Grade Plasmid DNA
      • Non-GMP Grade Plasmid DNA
      • By Application:
      • DNA Vaccines
      • Gene Therapy
      • Immunotherapy
      • Others
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Product Type:
      • High Quality (HQ) Plasmid DNA
      • GMP Grade Plasmid DNA
      • Non-GMP Grade Plasmid DNA
      • By Application:
      • DNA Vaccines
      • Gene Therapy
      • Immunotherapy
      • Others
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Product Type:
      • High Quality (HQ) Plasmid DNA
      • GMP Grade Plasmid DNA
      • Non-GMP Grade Plasmid DNA
      • By Application:
      • DNA Vaccines
      • Gene Therapy
      • Immunotherapy
      • Others
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Product Type:
      • High Quality (HQ) Plasmid DNA
      • GMP Grade Plasmid DNA
      • Non-GMP Grade Plasmid DNA
      • By Application:
      • DNA Vaccines
      • Gene Therapy
      • Immunotherapy
      • Others
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Product Type:
      • High Quality (HQ) Plasmid DNA
      • GMP Grade Plasmid DNA
      • Non-GMP Grade Plasmid DNA
      • By Application:
      • DNA Vaccines
      • Gene Therapy
      • Immunotherapy
      • Others
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Cobra Biologics and Pharmaceutical Services *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • VGXI, Inc.
    • Aldevron
    • Kaneka Corporation
    • Nature Application Corporation
    • PlasmidFactory GmbH & Co. KG
    • Cell and Gene Therapy Catapult
    • Waisman Biomanufacturing.
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Application
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Market Trends
  • Impact Analysis
  • Key Highlights
  • PEST Analysis
  • PORTER's Analysis
  • Mergers and Acquisitions
  • Epidemiology

4. Global Plasmid DNA Manufacturing Market, By Product Type, 2018 - 2026, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017- 2026
    • Segment Trends
  • High Quality (HQ) Plasmid DNA
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Mn)
  • GMP Grade Plasmid DNA
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Mn)
  • Non-GMP Grade Plasmid DNA
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Mn)

5. Global Plasmid DNA Manufacturing Market, By Application, 2018 - 2026, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017- 2026
    • Segment Trends
  • DNA Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Mn)
  • Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Mn)
  • Immunotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Mn)

6. Global Plasmid DNA Manufacturing Market, By Region, 2018 - 2026, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
  • North America
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Mn)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Mn)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Mn)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Mn)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Mn)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Product Type, 2018 - 2026, (US$ Mn)
    • Market Size and Forecast, By Application, 2018 - 2026, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

7. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
  • Company Profiles
    • Cobra Biologics and Pharmaceutical Services *
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • VGXI, Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Aldevron
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Kaneka Corporation
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Nature Application Corporation
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • PlasmidFactory GmbH & Co. KG
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Cell and Gene Therapy Catapult
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Waisman Biomanufacturing
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top
전화 문의
F A Q